CLINICAL_TRIALS trial_result · 2025-05-20

Clinical Trial Update: A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease [Phase 3]

A Phase 3 study of guselkumab in moderately to severely active Crohn's disease has completed, with results posted on 2025-05-20.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Janssen Pharmaceutical K.K. | Conditions: Crohns Disease | Phase 3 | Status: COMPLETED | Results posted: 2025-05-20